Outsourcing in Clinical Trials Nordics11-12 September 2013, Copenhagen, Denmark
With the Nordic biotech industry growing year on year, Arena are proud to present their newest event in the OCT series; Outsourcing in Clinical Trials Nordics. With the degree of outsourcing growing significantly within clinical trials, there comes a host of new challenges for pharmaceutical and biotech companies, and it has never been more important to ensure that vendors are used to their maximum ability and at minimal cost.
This Nordic-specific event will bring together senior industry representatives to discuss the latest challenges within clinical outsourcing such as vendor sourcing, selection and contracting, as well as communication, oversight and management. Outsourcing in Clinical Trials Nordics will present itself as a unique forum for discussion and idea-sharing on innovative strategies within outsourcing models in this ever-growing region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events. Here are just 7 of the reasons to attend our most popular event series.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
We are excited to announce that the Venue for the launch of OCT Nordics will be the Crowne Plaza Copenhagen Towers in Copenhagen, Denmark.
We now have a brand new group for the Outsourcing in Clinical Trials series on LinkedIn! Join the group for great ways to network with sponsors, speakers and delegates.
We are excited to host the first Outsourcing in Clinical Trials Nordics in Copenhagen, Denmark. Find out more about what to see from Copenhagen’s own tourist board VisitCopenhagen.
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer.
French pharmaceutical firm Sanofi has released results of a 24-week Phase IIIb clinical trial showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when given to patients either before breakfa…
US-based biopharmaceutical firm Lexicon Pharmaceuticals has released top-line results from an initial Phase II trial, designed to assess the use of its investigational drug LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d).
US-based biopharmaceutical firm Puma Biotechnology has released top line results from the I-SPY 2 Trial ('Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2') of its investigational drug PB272 (…
Denmark-based Novo Nordisk has announced that a Phase III trial of its investigational therapy IDegLira showed better control of blood sugar levels (HbA1c) compared with its own long-acting insulin Tresiba.